|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 07, 2012 ) New York, NY -- Shares of Cytosorbents Corp (CTSO) were moving this week on news that the company had received nearly four million dollars from a DARPA award to forward the company's flagship blood purification technology, CytoSorb. The award is pending satisfactory achievement of key milestones, according to information contained within the press release.
VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, offers broad insight into the transaction at the VFC's Stock House website: http://vfcsstockhouse.com/blog/article/-cytosorbents-ctso-moves-on-darpa-award
Cytosorbents' flagship product, CytoSorb, was approved last year in Europe for the treatment of severe sepsis and other indications where high cytokines are present in a patient's blood. Since the approval, the company has worked meticulously to launch the product - in Germany first - while keeping costs minimal in order to preserve company and shareholder value along the way.
Some investors wonder why such a potentially breakthrough product has not yet gained much more investor attention after the approval, however, and some of those concerns revolve around the small European trial size and lack of overwhelming support for the technology. The DARPA award addresses those concerns somewhat, as it comes as a nice sign of validation and confidence in the technology. DARPA has provided funding for much of this generation's "next-generation" technology - including the advent of the Internet - and any company welcomes the validation that DARPA money brings with it. To address the small European trial size, there may be some legitimacy to those concerns, but it's also telling that the European authorities approved CytoSorb before the final results for the trial were even compiled. That's huge, especially since there is no effective treatment for severe sepsis currently on the market. The days that CytoSorb treatment can cut off a stay in the Intensive Care unit can do wonders for the national health care plans that are eating away at national budgets in Europe and the medical regulators may have seen that.
These concerns, however, have not kept the CTSO share price from doubling and tripling at times as developments move the company forward. Just recently the CTSO share price was under a dime, making this latest run very significant in terms of percentages. As key developments continue to unfold, another visit to the highs achieved post-approval could materialize - those highs were well over forty cents, roughly a triple from this point.
For a full list of this week's hot stocks to watch visit: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-week-of-august-6-imsc-amrn-ssh-lptn-mric-sgyp-trov-ctso-celh-irwd-bsx-si-pfe-hgsi-gsk-dndn-fsx-clsp-fb-znga-ge-jcp-dis-m
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
